In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

In other recent news, Ginkgo Bioworks has reported significant developments. The company has announced a collaboration with Carnegie Mellon University on a project aimed at developing ...

BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Ginkgo Bioworks imply an improvement in the company's underlying business. Investors should show their ...

Ginkgo’s headquarters at 27 Drydock Ave. spans some 320,000 square feet, with leases that run from 2030 through 2036. The company has subleased 27,000 square feet, with another 129,000 square ...

The company still has a fairly decent balance sheet, but it is weakening by the quarter. Ginkgo finished last year with about $562 million in cash while being debt-free, but it had over $944 ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Sell rating on Ginkgo Bioworks Holdings (DNA – Research Report), with a ...

BOSTON, Feb. 21, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and ...